Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Novartis
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
GlaxoSmithKline
ImmunityBio, Inc.
AIO-Studien-gGmbH
M.D. Anderson Cancer Center